← Back to Calendar

Cogent Biosciences Q4 2025 Earnings

Cogent Biosciences · $COGT
Standard Review Earnings
Catalyst Date
February 25, 2026
Date Status
47d ago (past)
Review Type
Standard (10 mo)

Live Company Data NMS

Updated just now · Data: FMP
Current Price
$36.63 +759.74%
+$32.37 today
Day: $36.20 – $37.28
Market Cap
N/A
Shares out: 162.31M
Float: 150.97M
52-Week Range
$4.12
$43.73
Current price is at 82% of 52-week range
Avg Volume
2.15M
Beta
0.47
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $COGT catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Q4 2025 earnings + bezuclastinib APEX trial update

Key Notes

Q4 2025 earnings reported February 25, 2026. EPS -$0.61 (missed estimate of -$0.51). Net loss Q4 $102.5M. Update on bezuclastinib APEX Phase 2 trial in advanced systemic mastocytosis — data readout expected mid-2026.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar